|
1.
|
|
15 p, 877.1 KB |
Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis : APLIOS, a randomized phase-2 study
/
Bar-Or, Amit (University of Pennsylvania) ;
Wiendl, Heinz (University of Münster) ;
Montalban, Xavier (Hospital Universitari Vall d'Hebron) ;
Alvarez, Enrique (University of Colorado) ;
Davydovskaya, Maria (Pirogov Russian National Research Medical University) ;
Delgado, Silvia (University of Miami) ;
Evdoshenko, Evgeniy P. (St Petersburg Center for Multiple Sclerosis and Other Autoimmune Diseases) ;
Giedraitiene, Natasa (Vilnius University) ;
Gross-Paju, Katrin (Institute of Health Care Technology) ;
Haldre, Sulev (University of Tartu) ;
Herrman, Craig E. (JWM Neurology) ;
Izquierdo, Guillermo (Hospital Vithas Sevilla) ;
Karelis, Guntis (Riga East University Hospital) ;
Leutmezer, Fritz (Medical University of Vienna) ;
Mares, Miroslav (Pardubice Regional Hospital) ;
Meca-Lallana, Jose Eustasio (Hospital Universitario Virgen de la Arrixaca (Múrcia)) ;
Mickeviciene, Dalia (Lithuanian University of Health Sciences) ;
Nicholas, Jacqueline (Riverside Methodist Hospital) ;
Robertson, Derrick S. (University of South Florida) ;
Sazonov, Denis V. (Department of Clinical Trials FSBIH SDMC of FMBA of Russia) ;
Sharlin, Kenneth (Sharlin Health and Neurology) ;
Sundaram, Bharathy (Texas Institute for Neurological Disorders) ;
Totolyan, Natalia (Pavlov First State Medical University of St. Petersburg) ;
Vachova, Marta (Teplice Hospital) ;
Valis, Martin (Charles University) ;
Bagger, Morten (Novartis) ;
Häring, Dieter A. (Novartis) ;
Ludwig, Inga (Novartis) ;
Willi, Roman (Novartis) ;
Zalesak, Martin (Novartis) ;
Su, Wendy (Novartis) ;
Merschhemke, Martin (Novartis) ;
Fox, Edward J. (Central Texas Neurology Consultants PA) ;
Universitat Autònoma de Barcelona
Background: Ofatumumab, the first fully human anti-CD20 monoclonal antibody, is approved in several countries for relapsing multiple sclerosis (RMS). Objective: To demonstrate the bioequivalence of ofatumumab administered by an autoinjector versus a pre-filled syringe (PFS) and to explore the effect of ofatumumab on B-cell depletion. [...]
2022 -  10.1177/13524585211044479
Multiple sclerosis, Vol. 28 Núm. 6 (2022) , p. 910-924
|
|
|
2.
|
|
7 p, 813.8 KB |
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions
/
Cohen, Jeffrey A. (Mellen Center, Neurologic Institute, Cleveland Clinic) ;
Bermel, Robert (Mellen Center, Neurologic Institute, Cleveland Clinic) ;
Grossman, Cynthia I. (Biogen, Cambridge) ;
Hersh, Carrie (Cleveland Clinic (Las Vegas)) ;
Hyland, Megan. (University of Rochester. Department of Neurology) ;
Mowry, Ellen M. (Johns Hopkins University. Department of Neurology) ;
Naismith, Robert (Washington University in St. Louis. Department of Neurology) ;
Naylor, Maria L. (Biogen, Cambridge) ;
Nicholas, Jacqueline (OhioHealth Multiple Sclerosis Center) ;
Rajbhandar, Rajani (Biogen, Cambridge) ;
Singh, Carol M. (Biogen, Cambridge) ;
Tintoré, Mar (Hospital Universitari Vall d'Hebron) ;
Zabalza, Ana (Hospital Universitari Vall d'Hebron) ;
Ziemssen, Tjalf (University Clinic Carl-Gustav Carus. Department of Neurology) ;
Williams, James R. (Biogen, Cambridge) ;
Montalban, Xavier (Universitat Autònoma de Barcelona. Departament de Medicina)
The impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on SARS-CoV-2 vaccination response is uncertain. Post-SARS-CoV-2 vaccination blood samples across multiple DMTs were tested for SARS-CoV-2 immunoglobulin G (IgG) response. [...]
2022 - 10.1177/13524585211061343
Multiple sclerosis, Vol. 28 Num. 7 (january 2022) , p. 1131-1137
|
|
|
3.
|
|
14 p, 2.2 MB |
Associations of with clinico-radiological measures in a large population
/
Sotirchos, Elias S. (Johns Hopkins University School of Medicine) ;
Fitzgerald, Kathryn (Johns Hopkins University School of Medicine) ;
Singh, Carol (Biogen) ;
Smith, Matthew D. (Johns Hopkins University School of Medicine) ;
Reyes-Mantilla, Maria (Johns Hopkins University School of Medicine) ;
Hersh, Carrie (Cleveland Clinic) ;
Hyland, Megan H. (University of Rochester Medical Center) ;
Canissario, Ryan (University of Rochester Medical Center) ;
Simmons, Sarah B. (Mellen Center, Neurological Institute, Cleveland Clinic) ;
Arrambide, Georgina (Hospital Universitari Vall d'Hebron) ;
Montalban, Xavier (Hospital Universitari Vall d'Hebron) ;
Comabella, Manuel (Hospital Universitari Vall d'Hebron) ;
Naismith, Robert (Washington University in St. Louis) ;
Qiao, Min (Washington University in St. Louis) ;
Krupp, Lauren B. (New York University) ;
Nicholas, Jacqueline A. (Riverside Methodist Hospital) ;
Akgün, Katja (University Clinic Carl-Gustav Carus) ;
Ziemssen, Tjalf (University Clinic Carl-Gustav Carus) ;
Rudick, Richard ((formerly) Biogen) ;
Fisher, Elizabeth (Biogen) ;
Bermel, Robert (Mellen Center, Neurological Institute, Cleveland Clinic) ;
Mowry, Ellen (Johns Hopkins University School of Medicine) ;
Calabresi, Peter A. (Johns Hopkins University School of Medicine) ;
Universitat Autònoma de Barcelona
Evaluation of serum neurofilament light chain (sNfL), measured using high-throughput assays on widely accessible platforms in large, real-world MS populations, is a critical step for sNfL to be utilized in clinical practice. [...]
2022 - 10.1002/acn3.51704
Annals of Clinical and Translational Neurology, Vol. 10 (november 2022) , p. 84-97
|
|
|
4.
|
|
15 p, 865.1 KB |
Harnessing Real-World Data to Inform Decision-Making : Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS)
/
Mowry, Ellen M. (Johns Hopkins University) ;
Bermel, Robert (Cleveland Clinic) ;
Williams, James R. (Biogen) ;
Benzinger, Tammie L. S. (Washington University in St. Louis) ;
de Moor, Carl (Biogen) ;
Fisher, Elizabeth (Biogen) ;
Hersh, Carrie M. (Cleveland Clinic Lou Ruvo Center for Brain Health) ;
Hyland, Megan H. (University of Rochester Medical Center) ;
Izbudak, Izlem (Johns Hopkins University) ;
Jones, Stephen E. (Cleveland Clinic) ;
Kieseier, Bernd C. (Biogen) ;
Kitzler, Hagen H. (University Clinic Carl Gustav Carus, TU Dresden) ;
Krupp, Lauren (New York University) ;
Lui, Yvonne W. (New York University) ;
Montalban, Xavier (Hospital Universitari Vall d'Hebron) ;
Naismith, Robert T. (Washington University in St. Louis) ;
Nicholas, Jacqueline A. (OhioHealth) ;
Pellegrini, Fabio (Biogen) ;
Rovira, Alex (Hospital Universitari Vall d'Hebron) ;
Schulze, Maximilian (University Hospital of Giessen and Marburg (Alemanya)) ;
Tackenberg, Björn (University Hospital of Giessen and Marburg (Alemanya)) ;
Tintoré, Mar (Hospital Universitari Vall d'Hebron) ;
Tivarus, Madalina E. (University of Rochester Medical Center) ;
Ziemssen, Tjalf (Center of Clinical Neuroscience, University Clinic Carl Gustav Carus, TU Dresden) ;
Rudick, Richard A. (Biogen) ;
Universitat Autònoma de Barcelona
Background: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) is the first example of a learning health system in multiple sclerosis (MS). This paper describes the initial implementation of MS PATHS and initial patient characteristics. [...]
2020 - 10.3389/fneur.2020.00632
Frontiers in neurology, Vol. 11 (august 2020)
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
